当前位置: 首页 >> 检索结果
3141. Effects of diuretic therapy on the development of tolerance to nitroglycerin and exercise capacity in patients with chronic stable angina.
Therapy with diuretics has been reported to prevent the development of nitrate tolerance. Importantly, diuretics may have independent antianginal effects through their effects on intravascular volume. The present investigation was designed to determine whether diuretic therapy could prevent the development of tolerance to continuous transdermal nitroglycerin. The study was also designed to examine whether diuretic therapy has an independent antianginal effect.
3143. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study.
作者: E F Wever.;R N Hauer.;G Schrijvers.;F J van Capelle.;J G Tijssen.;H J Crijns.;A Algra.;H Ramanna.;P F Bakker.;E O Robles de Medina.
来源: Circulation. 1996年93卷3期489-96页
Rising costs of health care, partly as a result of costly therapeutic innovations, are of concern to both the medical profession and healthcare authorities. The implantable cardioverter-defibrillator (ICD) is still not remunerated by Dutch healthcare insurers. The aim of this study was to evaluate the cost-effectiveness of early implantation of the ICD in postinfarct sudden death survivors.
3144. Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependence analysis based on pressure-volume relations.
作者: M D Feldman.;P H Pak.;C C Wu.;H L Haber.;C M Heesch.;J D Bergin.;E R Powers.;T D Cowart.;W Johnson.;A M Feldman.;D A Kass.
来源: Circulation. 1996年93卷3期474-83页
OPC-18790 is a water-soluble quinolinone derivative that shares the pharmacological properties of vesnarinone and that may be useful for treating heart failure. We studied the contribution and relative dose sensitivities of the inotropic, lusitropic, and vascular effects of OPC-18790 in patients with dilated cardiomyopathy.
3145. Simultaneous transmission/emission myocardial perfusion tomography. Diagnostic accuracy of attenuation-corrected 99mTc-sestamibi single-photon emission computed tomography.
作者: E P Ficaro.;J A Fessler.;P D Shreve.;J N Kritzman.;P A Rose.;J R Corbett.
来源: Circulation. 1996年93卷3期463-73页
The purpose of the present study was to assess the diagnostic performance of attenuation-corrected (AC) stress 99mTc-sestamibi cardiac single-photon emission computed tomography (SPECT) for the identification of coronary heart disease (CHD).
3147. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial.3148. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.
作者: P Hall.;S Nakamura.;L Maiello.;A Itoh.;S Blengino.;G Martini.;M Ferraro.;A Colombo.
来源: Circulation. 1996年93卷2期215-22页
Previous studies have shown that it is feasible to withhold anticoagulation after a successful intracoronary stent procedure with a low incidence of stent thrombosis. The importance of specific antiplatelet agents when stenting is performed without anticoagulation is unknown.
3149. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study.
作者: S M Bode-Böger.;R H Böger.;H Alfke.;D Heinzel.;D Tsikas.;A Creutzig.;K Alexander.;J C Frölich.
来源: Circulation. 1996年93卷1期85-90页
L-Arginine is the precursor of endogenous nitric oxide (NO), which is a potent vasodilator acting via the intracellular second-messenger cGMP. In healthy humans, L-arginine induces peripheral vasodilation and inhibits platelet aggregation due to an increased NO production. Prostaglandin E1 (PGE1) induces peripheral vasodilation via stimulating prostacyclin receptors.
3150. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
作者: M Gent.;J Hirsh.;J S Ginsberg.;P J Powers.;M N Levine.;W H Geerts.;R M Jay.;J Leclerc.;J A Neemeh.;A G Turpie.
来源: Circulation. 1996年93卷1期80-4页
The study objective was to determine the relative efficacy and safety of a low-molecular-weight heparinoid (Orgaran) compared with aspirin for the prevention of postoperative venous thromboembolism in patients undergoing surgery for fractured hips. A double-blind, randomized, controlled trial was used to study 251 consecutive eligible and consenting patients undergoing surgery for hip fracture in seven participating hospitals.
3151. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
作者: S P Azen.;W J Mack.;L Cashin-Hemphill.;L LaBree.;A M Shircore.;R H Selzer.;D H Blankenhorn.;H N Hodis.
来源: Circulation. 1996年93卷1期34-41页
Progression of coronary artery disease is assumed to be a surrogate end point for clinical coronary events. Because no single method or measure for a coronary angiographic end point is uniformly accepted as optimal, the utility and validity of surrogate end points for predicting clinical coronary events remain unsettled.
3152. Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients.
作者: Y S Tuininga.;H J Crijns.;J Brouwer.;M P van den Berg.;A J Man in't Veld.;G Mulder.;K I Lie.
来源: Circulation. 1995年92卷12期3415-23页
Physical exercise and mental work cause alterations in cardiac autonomic control. beta-Blockers protect the heart against stress, and this effect may be in part centrally mediated. In this context, the lipophilicity of the drug would be clinically relevant.
3154. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.
作者: M M Scheinman.;J H Levine.;D S Cannom.;T Friehling.;H A Kopelman.;D A Chilson.;E V Platia.;D J Wilber.;P R Kowey.
来源: Circulation. 1995年92卷11期3264-72页
Oral amiodarone effectively suppresses ventricular arrhythmias; however, full activity may take days or weeks. In patients with frequent, life-threatening ventricular arrhythmias, this delay is not acceptable. Thus, in these patients, the speed and dosing accuracy of an intravenous formulation would be beneficial. The goal of this study was to demonstrate the efficacy of intravenous amiodarone in patients with refractory, recurrent hemodynamically destabilizing ventricular tachycardia or ventricular fibrillation by determining a dose response among three regimens.
3155. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group.
作者: P R Kowey.;J H Levine.;J M Herre.;A Pacifico.;B D Lindsay.;V J Plumb.;D L Janosik.;H A Kopelman.;M M Scheinman.
来源: Circulation. 1995年92卷11期3255-63页
After several days of loading, oral amiodarone, a class III antiarrhythmic, is highly effective in controlling ventricular tachyarrhythmias; however, the delay in onset of activity is not acceptable in patients with immediately life-threatening arrhythmias. Therefore, an intravenous form of therapy is advantageous. This study was designed to compare the safety and efficacy of a high and a low dose of intravenous amiodarone with bretylium, the only approved class III antiarrhythmic agent.
3156. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II).
作者: M P Savage.;S Goldberg.;A A Bove.;E Deutsch.;G Vetrovec.;R G Macdonald.;T Bass.;J R Margolis.;H B Whitworth.;A Taussig.
来源: Circulation. 1995年92卷11期3194-200页
Antithromboxane therapy with aspirin reduces acute procedural complications of coronary angioplasty (PTCA) but has not been shown to prevent restenosis. The effect of chronic aspirin therapy on long-term clinical events after PTCA is unknown, and the utility of more specific antithromboxane agents is uncertain. The goal of this study was to assess the effects of aspirin (a nonselective inhibitor of thromboxane A2 synthesis) and sulotroban (a selective blocker of the thromboxane A2 receptor) on late clinical events and restenosis after PTCA.
3157. ESVEM tells us what we don't know.3158. A prospective randomized evaluation of implantable cardioverter-defibrillator size on unipolar defibrillation system efficacy.
作者: G K Jones.;J E Poole.;P J Kudenchuk.;G L Dolack.;G Johnson.;P DeGroot.;M J Gleva.;M Raitt.;G H Bardy.
来源: Circulation. 1995年92卷10期2940-3页
The active can unipolar implantable cardioverter-defibrillator (ICD) has been shown to defibrillate efficiently, but its current 80-cc size limits use in the pectoral position in many patients. Decreasing can size will facilitate pectoral insertion and will soon be feasible as an inevitable consequence of technological advancements. However, decreasing the can size has the potential to compromise unipolar defibrillation efficacy. It is the purpose of this study, therefore, to prospectively and randomly compare unipolar defibrillation efficacy with 80-cc, 60-cc, and 40-cc can sizes in patients immediately before ICD surgery in anticipation of advances in technology that will make smaller ICDs possible.
3159. Steroid elution improves the stimulation threshold in an active-fixation atrial permanent pacing lead. A randomized, controlled study. Model 4068 Investigators.
作者: G H Crossley.;J A Brinker.;D Reynolds.;W Spencer.;W B Johnson.;H Hurd.;L Tonder.;M Zmijewski.
来源: Circulation. 1995年92卷10期2935-9页
Prior work suggests that the addition of a steroid-eluting reservoir to a passive-fixation permanent pacemaker lead improves the stimulation threshold; however, no large randomized study has addressed this tissue. Over the last several years, there has been an increase in enthusiasm for the use of active-fixation permanent pacemaker leads for various reasons in spite of the generally accepted notion that active-fixation leads have higher stimulation thresholds.
3160. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects.
N-acetylcysteine (NAC) has been shown to potentiate the effects of nitroglycerin (NTG) and to have antioxidant activity. This is the first study to assess the safety and effect of NAC in the treatment of evolving acute myocardial infarction (AMI).
|